Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.47%) $27.23
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Realaus laiko atnaujinimai Satsuma Pharmaceuticals [STSA]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Atnaujinta7 birž. 2023 @ 23:00
25% discount on Stockinvest.us - Use code: Podcast

0.00% $ 1.100

Live Chart Being Loaded With Signals

Commentary (7 birž. 2023 @ 23:00):
Profile picture for Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device...

Stats
Šios dienos apimtis 1.83M
Vidutinė apimtis 1.11M
Rinkos kapitalizacija 36.47M
EPS $0 ( 2024-03-26 )
Kita pelno data ( $0 ) 2024-05-09
Last Dividend $0.200 ( 2014-03-28 )
Next Dividend $0 ( N/A )
P/E -0.553
ATR14 $0.0510 (4.64%)
Insider Trading
Date Person Action Amount type
2023-06-08 Ra Capital Management, L.p. Sell 5 914 252 Common Stock
2023-06-08 Ra Capital Management, L.p. Sell 10 000 Stock Option (Right to Buy)
2023-06-08 Ra Capital Management, L.p. Sell 20 000 Stock Option (Right to Buy)
2023-06-08 Ra Capital Management, L.p. Sell 30 000 Stock Option (Right to Buy)
2023-06-06 O'neil Thomas P. Sell 13 877 Common Stock, $0.0001 par value
INSIDER POWER
54.69
Last 97 transactions
Buy: 62 291 817 | Sell: 17 994 879

Tūris Koreliacija

Ilgas: 0.14 (neutral)
Trumpas: 0.49 (neutral)
Signal:(60.819) Neutral

Satsuma Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
NRBO0.956
DLTH0.937
NXTC0.934
TFFP0.933
TOI0.93
AGLE0.923
PRTK0.923
VIAV0.917
ONCS0.914
SGRP0.914
10 Labiausiai neigiamai susiję koreliacijos
AGFS-0.944
APEN-0.938
PRDO-0.932
NRIM-0.92
FANH-0.916
VLYPO-0.916
UFPT-0.916
MACK-0.914
TSBK-0.91
AMRB-0.906

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Satsuma Pharmaceuticals Koreliacija - Valiuta/Žaliavos

The country flag 0.31
( neutral )
The country flag 0.35
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )
The country flag -0.25
( neutral )
The country flag 0.12
( neutral )

Satsuma Pharmaceuticals Finansinės ataskaitos

Annual 2022
Pajamos: $0
Bruto pelnas: $0 (0.00 %)
EPS: $-2.16
FY 2022
Pajamos: $0
Bruto pelnas: $0 (0.00 %)
EPS: $-2.16
FY 2021
Pajamos: $0.00
Bruto pelnas: $0.00 (0.00 %)
EPS: $-1.623
FY 2020
Pajamos: $0.00
Bruto pelnas: $0.00 (0.00 %)
EPS: $-2.73

Financial Reports:

No articles found.

Satsuma Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A)

Satsuma Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A
Information
First Dividend $0.150 2012-12-19
Last Dividend $0.200 2014-03-28
Next Dividend $0 N/A
Payout Date 2014-04-15
Next Payout Date N/A
# dividends 7 --
Total Paid Out $1.500 --
Avg. Dividend % Per Year 0.00% --
Score 1.57 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
 (2024-06-10)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
1.57
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM01.50000[0 - 0.5]
returnOnAssetsTTM-1.0861.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM1.3391.50010.0010.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM7.440.80010.008.00[1 - 3]
quickRatioTTM7.090.80010.008.00[0.8 - 2.5]
cashRatioTTM3.351.50010.0010.00[0.2 - 2]
debtRatioTTM0.00267-1.5009.96-10.00[0 - 0.6]
interestCoverageTTM107.961.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-1.1132.00-0.371-0.742[0 - 30]
freeCashFlowPerShareTTM-1.1172.00-0.559-1.117[0 - 20]
debtEquityRatioTTM0.00308-1.5009.99-10.00[0 - 2.5]
grossProfitMarginTTM01.000-3.33-3.33[0.2 - 0.8]
operatingProfitMarginTTM01.000-2.00-2.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-318.091.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score3.51

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.7731.000-0.1790[1 - 100]
returnOnEquityTTM1.3392.501.15210.00[0.1 - 1.5]
freeCashFlowPerShareTTM-1.1172.00-0.372-1.117[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-1.1132.00-0.371-0.742[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.005341.500-3.300[0.5 - 2]
operatingCashFlowSalesRatioTTM01.000-2.500[0.1 - 0.5]
Total Score-0.623

Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.